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Selective and targeted delivery of drugs to tumors is a major challenge for an effective
cancer therapy and also to overcome the side-effects associated with current treatments.
Overexpression of various receptors on tumor cells is a characteristic structural and bio-
chemical aspect of tumors and distinguishes them from physiologically normal cells. This
abnormal feature is therefore suitable for selectively directing anticancer molecules to
tumors by using ligands that can preferentially recognize such receptors. Several subtypes
of integrin receptors that are crucial for cell adhesion, cell signaling, cell viability, and motil-
ity have been shown to have an upregulated expression on cancer cells.Thus, ligands that
recognize specific integrin subtypes represent excellent candidates to be conjugated to
drugs or drug carrier systems and be targeted to tumors. In this regard, integrins recog-
nizing the RGD cell adhesive sequence have been extensively targeted for tumor-specific
drug delivery. Here we review key recent examples on the presentation of RGD-based
integrin ligands by means of distinct drug-delivery systems, and discuss the prospects of
such therapies to specifically target tumor cells.
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INTRODUCTION
Cancer diagnosis, therapy, and monitoring represent fundamen-
tal topics of research in medicine and are of utmost importance
in healthcare of today’s society. An efficient cancer therapy should
possess exceptional abilities not only to ensure a complete removal
Abbreviations: A549, human non-small cell lung carcinoma; ATCC, CCL-185
cells; ATCC, HTB-65 cells; bFGF, basic fibroblast growth factor; BMEC, brain
microvascular endothelial cells; Cap-RGD, Ac-CCVVVTGRGDSPSSK-COOH;
DCP-TEPA, dicetylphosphate-tetraethylenepentamine; DOPE, dioleoylphos-
phatidylethanolamine; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine;
DSPC, distearoylphosphatidylcholine; DSPE, distearoylphosphatidylethanolamine;
DTPA, diethylenetriamenepentaacetate; FDG, fluoro-2-deoxy-d-glucose; HEK,
human embryonic kidney; HeLa, human cervical carcinoma cells; HPAE-co-
PLA/DPPE, poly[(amine-ester)-co-(d,l-lactide)]/1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine copolymer; HPMA, N -(2-hydroxypropyl)methacrylamide;
HAS, human serum albumin; HUVEC, human umbilical vein endothelial
cells; IV, intravenous; Luc-pDNA, luciferase pDNA; Mal-PEG-PCL, maleimide-
poly(ethylene glycol)-block-poly(ε-caprolactone); MDR, multi-drug resistance;
MeWo, human malignant skin melanoma; MMAE, monomethyl-auristatin-E;
MRI, magnetic resonance imaging; NSCLC, non-small cell lung cancer; PCL-PEEP,
poly(ε-caprolactone)-block-poly-(ethyl ethylene phosphate); pCMVLuc, Photinus
pyralis luciferase under control of the CMV enhancer/promoter; PEG, polyethylene
glycol; PEI, polyethylenimine; PEO-b-PCL, poly(ethylene oxide)-block-poly(ε-
caprolactone); PET, positron emission tomography; PGA, poly-glutamic acid; PLA,
poly(lactic acid); PLG, poly-l-glutamic acid; PLGA, poly (d,l-lactide-co-glycolide);
PLL, poly (l-lysine); PLys, polylysine; pORF-hTRAIL, plasmid expressing the
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); P(PEGMEMA),
poly[poly(ethylene glycol) methyl ether methacrylate]; sFlt-1, soluble fms-like
tyrosinekinase-1 (pDNA encoding the soluble form of VEGF receptor-1); SPECT,
single-photon emission computed tomography; TAT peptide, CGRKKRRQRRR;
Tf, transferrin; TfR, transferrin receptor; TLT, transplantable liver tumors; VEGF,
vascular endothelial growth factors.
of the tumor but also to prevent its spreading and invasion to
other tissues by metastasis. Current clinical approaches to treat
cancer include, and often combine, surgery, chemotherapy, radia-
tion therapy as well as immunotherapy. However, these methods
in general still fail to treat highly aggressive metastatic cancers,
and present some serious limitations. For instance, irradiation of
tumors may damage adjacent healthy tissues, and chemotherapy,
which is based on a non-specific systemic distribution regime,
requires high drug dosage and promotes severe adverse side effects.
For example, the administration of Paclitaxel (PTX), a drug used
for the treatment of lung, ovarian, and breast cancers, has been
associated with unwanted effects such as hypersensitivity reac-
tions, myelosuppression, and neurotoxicity (1, 2), among others.
Doxorubicin (DOX), another drug used in cancer chemotherapy,
has also been described to have cardiotoxic side effects (3, 4).
Moreover, chemotherapy might turn inefficient due to acquired
chemoresistance as exemplified in the case of Gemcitabine – prime
therapeutic used to treat pancreatic cancers (5), for DOX (3) and
also for PTX (6, 7).
Tumor targeted drug-delivery (Figure 1) represents a promis-
ing approach to overcome some of the above mentioned lim-
itations (8). This strategy aims to specifically guide and direct
anticancer therapeutics (or imaging agents) to tumor cells with-
out interfering with normal tissues. Such targeted approach relies
on the fact that tumor vasculature and tumor cells display a
well-differentiated pattern of (over-)expression of specific recep-
tors (i.e., receptors required for tumor angiogenesis), which is
consistent with the concept of “Vascular Zip Codes” (9, 10). Tar-
geted drug-delivery methods hence employ small molecules or
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FIGURE 1 | Schematic representation of the principle of tumor targeted drug delivery for treating cancer.
FIGURE 2 | (A) Integrin recognition motif RGD; (B) schematic representation of cyclic RGD (cRGD); (C) Cilengitide – c(RGDf-NMeVal); (D) peptide sequences
of RGD4C (the green curves indicate disulfide bridges), α5β1 ligand PR_b, and αvβ6 ligand A20FMDV2.
monoclonal antibodies selective to receptors that are proven to be
abnormally expressed on tumors. The conjugation of anticancer
drugs to these selective ligands will allow a preferential or selective
delivery of the drug to the tumor.
As a result, this technique benefits from several advantages: (i)
non-specific interactions with normal tissues are reduced,and thus
the adverse side-effects associated to conventional chemother-
apy can be minimized. (ii) Site-directed drug release leads to
higher local concentrations at the diseased tissue and thus allows
dosage reduction. (iii) Acquired chemoresistance can potentially
be reduced by co-delivering other therapeutics capable of regulat-
ing cancer multi-drug resistance (MDR). To avail these advantages,
well accessible cell surface receptors are preferred over intracellular
targets where (complex) drug internalization mechanisms need
to be taken into consideration. In this regard, one of the most
intensely referred class of proteins for targeted therapy is the
integrin family (11).
Integrins are heterodimeric transmembrane glycoproteins con-
sisting of an α and a β subunit. In total, 24 different subtypes of
integrins that are constituted from 18 α and 8 β subunits have been
discovered to date (12). Almost half of them bind to various extra
cellular matrix (ECM) proteins such as fibronectin, vitronectin,
and collagen through the tripeptide motif Arg-Gly-Asp=RGD
[(13), Figure 2], and are vital in the adhesion, signaling, migration,
and survival of most cells (14). Integrins have also very important
roles in cancer progression and some subtypes have been described
to be highly over-expressed on many cancer cells. This is the case
of integrins αvβ3, αvβ5, and α5β1, which are crucial mediators
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of angiogenesis in cancer (8, 15–17). Underlying cause for this is
the elevated demand by the enlarging tumor for adequate sup-
ply of necessary nutrients and oxygen. In order to meet these
demands through blood supply, tumor tissue with a rapidly over-
growing number of cells, signals [via growth factors like vascular
endothelial growth factor (VEGF) or basic fibroblast growth factor
(bFGF)] for increased angiogenesis, a state known as “angiogenic
switch.” Sprouting of new blood vessels and overexpression of
integrins in tumor tissues and vasculature are thus key features in
the pathophysiology of cancer. Other integrins such as αvβ6 and
α6β4 are also observed to be expressed on tumor cells (8). Another
pivotal function of integrins is the promotion of cell migration by
virtue of their binding to ECM components. This phenomenon
is responsible for the process of tumor proliferation, migration,
invasion, and metastasis (18). These functional aspects together
with the high expression levels found on tumor cells have con-
verted integrins into very interesting proteins for targeted cancer
diagnosis and therapy studies.
Our review shortly recapitulates recent developments in inte-
grin targeted cancer therapy, with special focus on targeted deliv-
ery of chemotherapy or gene therapy via non-viral vectors like
nanoparticles (NPs), micelles, vesicles, or other systems grafted
with RGD-based integrin ligands. Considering the vastness of
the topic, we have only cited a limited amount of recent works.
For previous studies and developments in this field other detailed
reviews are available (19–22). Applications based on integrin tar-
geting antibodies and therapies involving the blocking of integrin
functions with antagonists and other ligands are not subject of this
review.
INTEGRIN LIGANDS AND INTEGRIN TARGETING
Since the discovery of the integrin recognizing RGD motif by
Ruoslahti et al. (13, 23), extensive research has been carried
out to develop RGD-based peptide and peptidomimetic inte-
grin ligands (24). Various synthetic strategies have been applied
to develop RGD peptide analogs with enhanced biological prop-
erties and pharmacokinetics like affinity and selectivity for dif-
ferent integrin subtypes, metabolic stability, and biodistribution.
These strategies include the introduction of amino acids flank-
ing the tripeptidic RGD sequence, cyclization, and variation of
stereochemical configuration of the constituent amino acids (25),
and N-methylation (26, 27) (Figure 2). Cilengitide – c(RGDf-
NMeVal) (Figure 2), a very potent antagonist of αvβ3, was devel-
oped by using some of these approaches and has been clinically
tested by Merck primarily for treatment of glioblastoma multi-
forme (28, 29). Despite promising preliminary data, its use as
anticancer therapeutic has been discontinued due to failure in
phase-III clinical trials (Merck press release on Cilengitide stud-
ies: http://www.merck.de/de/presse/extNewsDetail.html?newsId=
C47977D13865FCB9C1257B1D001EF9CA&newsType=1). Other
well-known RGD peptides are cRGDfV (25) – the parent peptide
for Cilengitide, cRGDfK (30), and RGD4C (ACDCRGDCFCG)
(31). RGD4C is susceptible to be expressed by recombinant meth-
ods into proteins and viruses for their targeted delivery. Targeting
integrins using cRGDfX, cRGDeV, cRGDyV, and other peptides
or peptidomimetics (Figure 2) has also been reported in the
literature.
TARGETED DRUG DELIVERY
Targeted delivery can be accomplished by two approaches: the
direct conjugation of the targeting motif to the drug or the use of
drug vehicular systems grafted with the targeting motif. Of these,
the use of carrier systems offers several advantages compared to
direct conjugation methods:
1. Carrier systems have the capacity to present multiple ligands
on each particle. This facilitates effective targeting via multi-
ple and simultaneous interactions between the ligands and the
receptors, exploiting the concept of multivalency.
2. Vehicular systems may keep the drug unexposed to physi-
ological systems, thereby protecting it from degradation or
alteration, and more importantly, minimizing undesirable non-
specific interactions of the drug with normal tissues. Therefore,
these systems may remarkably reduce the side effects of the
drug.
3. Targeted carrier systems usually are internalized via receptor-
mediated endocytosis and the drug is directly released within
cell. This is more effective to attain higher in-cell drug
concentrations for amplified therapeutic activity.
4. Being larger in size (∼>100 nm) than classical drugs, carrier
systems are not filtered off by renal pathways (size limit for
renal filtration∼5 nm). This enables a prolonged half-life time
of carrier particles in the blood stream and allows for a gradual
release of the drug over longer periods of time. Such release
kinetics avoid high systemic concentrations of the drug and
improves the effectiveness of the administered dose.
5. The abnormal architecture and permeability of tumor vascu-
lature promotes extravasation of the particles that are in blood
circulation. This phenomenon is called enhanced permeability
and retention (EPR) effect. Facilitated by this passive transport
mechanism, the nano-sized vehicular systems enter into tumor
tissues. However, the quick clearance of these NPs from the
tissue is prevented by their large size and lead to prolonged
retention times in tumor. Hence, the double targeting – passive
and active receptor-mediated targeting, enhances therapeutic
efficacy.
Among the carrier systems, viral vectors such as retroviruses
and adenoviruses have been successfully developed and found to
be efficient in targeted gene therapy (32). However, their use is
associated with several disadvantages that have precluded their
clinical application. In the first place, they can produce unwanted
immune responses (33). Also, it is not easy to express viruses
composed with targeting moieties that contain unnatural amino
acids or chemically modified scaffolds. Moreover, viral vectors can
only be used for gene therapy and are not suitable for delivery of
chemotherapeutics. Last but not least, they also carry a negative
public perception concerning safety (33, 34). Therefore, develop-
ment of non-viral targeting vectors is a preferred alternative in
targeted therapy. In this regard, various kinds of polymer-based
nanocarriers have been developed for tumor targeting using inte-
grin ligands including the use of RGD coated virus like particles
(VLPs) which use only the capsid of the viruses (35). In the follow-
ing sections, some representative examples are discussed according
to the targeted integrin subtype.
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TARGETING αvβ3 AND αvβ5 INTEGRINS
As previously introduced, the αvβ3 integrin subtype plays a major
role in angiogenesis, tumor neovascularization, and tumor metas-
tasis (8). The angiogenic pathways dependent on αvβ3 have been
described to be induced by bFGF or tumor necrosis factor α (TNF-
α). Its expression is upregulated on angiogenic endothelial cells
(36–38) and on various tumor cell lines (39, 40). Antagonistic inhi-
bition of αvβ3 integrin has been shown to suppress angiogenesis
(41) and to induce apoptosis (42). The well-established biolog-
ical roles, high expression on tumor tissues, and the availability
of ligands with high affinity, have set αvβ3 the most extensively
studied integrin for tumor targeting. The integrin αvβ5 is also
involved in angiogenesis but through a distinct pathway stimu-
lated by VEGF or transforming growth factor α (TGF-α) (16).
Since most RGD-containing peptidic αvβ3 antagonists also recog-
nizeαvβ5, although usually with a lower affinity, these two integrin
subtypes are discussed together.
TARGETED DELIVERY OF CHEMOTHERAPY USING POLYMERIC VEHICLES
Encapsulation of drugs in polymer-based carrier systems is a prac-
tical approach to protect them from degradation in biological
system. Furthermore, these systems may reduce the systemic tox-
icity of the drug and also enhance their safe elimination from
the physiological system. In addition, these vehicles often amelio-
rate the drug’s pharmacokinetic profile and biological distribution
within the organism. Phospholipid or polypeptide-based poly-
mers are commonly employed to prepare drug-delivery vehicles
as they are akin to biological molecular components and thus
display low toxicity and are easily biodegradable. Since the physic-
ochemical properties of these polymers can be easily tuned to
produce liposomes, micelles, or NPs, via well-established proto-
cols, these materials are frequently used to construct drug-delivery
vehicles. In fact, liposomes have already been used for the formu-
lation and delivery of DOX (4). These vehicles may additionally
be PEGylated to improve their aqueous solubility and to reduce
non-specific interactions with plasma proteins and membranes.
Besides encapsulation, drugs can as well be bound to these sys-
tems by chemical methods. This enables drug stability and also
secured pH-sensitive release of drugs in situ. These sorts of carrier
systems have been equipped with integrin targeting ligands and
experimented for their capabilities as targeted drug-delivery sys-
tems in cancer treatment. Some illustrative recent works are listed
in Table 1.
TARGETED DELIVERY OF CHEMOTHERAPY USING PROTEIN-BASED NPs
Although polymer-based vehicle systems are a common choice
for drug delivery, their long-term biological toxicity might be an
issue and needs to be carefully assessed. For this reason, protein-
based NPs are considered an attractive alternative for targeted
therapy due to their high biocompatibility, biodegradable prop-
erties, and water solubility. With regard to this, albumin is one
of the proteins that has been most majorly explored for drug
delivery. For example, linking c(RGDyK)C to albumin NPs loaded
with Gemcitabine showed an increased in vitro and in vivo anti-
tumor efficacy in BxPC-3 pancreatic cancer cell lines compared
to NPs without the targeting sequence (43). The conjugation of
cyclic RGD to albumin not only lead to successful targeting but
also increased the intracellular uptake of NPs and Gemcitabine as
monitored by florescence studies. The αvβ3-mediated uptake of
the RGD-conjugated components into pancreatic cells was further
confirmed by competitive inhibition studies using soluble RGD
ligands. In another study (44), Fluorouracil-bearing cRGDfK-
albumin nanospheres have shown significant improvement in
binding to αvβ3-expressing HUVEC cells in vitro. A considerable
improvement in prevention of lung metastasis and angiogenesis,
and in tumor regression was observed in vivo in B16F10 tumor-
bearing mice as compared with the activity of the free drug. The
binding of nanospheres conjugated with RGD to endothelial cells
was eightfold higher than that of nanospheres without RGD or
conjugated with the RAD sequence (which does not bind to inte-
grins). Similarly, enhanced homing to tumors and endothelial
cell binding were reported for cRGDfK-PEG-albumin NPs that
were linked to the antimitotic agent monomethyl-auristatin-E
(MMAE) (45). These studies were carried out on HUVECs and
C26 carcinoma-bearing mice. Two kinds of target systems were
prepared with an RGD peptide linked to albumin either by a
PEG chain (RGD-PEG-MMAE-HSA) or a short alkyl chain (RGD-
MMAE-HSA). After IV administration in mice, fluorescent studies
showed colocalization of both carrier systems with the tumor
vasculature and tumor cells.
Besides the use of albumin as drug-delivery system, spider silk
is a protein that holds great promise for application in targeted
therapies. Due to its water solubility, excellent biocompatibil-
ity, and unique mechanical properties, spider silk has attracted
growing interest in a number of biomedical areas. Spider silks
are currently under investigation for the encapsulation and con-
trolled release of drugs and growth factors, with so far optimistic
outcomes (46). Scheibel’s group has prepared spider silks con-
taining the integrin recognition motifs GRGDSP or cRGDfK
by either recombinant expression or chemical methods, respec-
tively (47). These RGD functionalized proteins have been used
to generate spider silk films that retain the biophysical proper-
ties observed for silks prepared using the native proteins. Sig-
nificant improvements in the attachment and proliferation of
BALB/3T3 mouse fibroblasts were observed on films containing
the RGD sequence but not on unmodified or RGE-containing
silk. These results encourage further exploration of spider silk pro-
tein as a prospective carrier system for targeted drug delivery in
cancer.
TARGETED DELIVERY OF CHEMOTHERAPY USING METALLIC NPs
Gold and other metallic NPs can be used for the polyvalent display
of targeting scaffolds (48). Ease of preparation and functionaliza-
tion as well as unique physicochemical properties make gold NPs
very attractive systems for use in cancer diagnosis and therapy. For
instance, PEGylated gold NPs coupled to a cRGD peptidomimetic
via thiol chemistry showed good affinity and binding to αvβ3-
positive PC-3 prostate cancer cells in vitro (49). In another study,
Yang et al. have examined the utility of multifunctional PEGylated
superparamagnetic iron oxide (SPIO) NPs in targeted drug deliv-
ery and PET/Magnetic Resonance Imaging (MRI) (50). To this
end, cRGDfC and a common 64Cu chelator were bound to the
distal ends of the PEG chains, whereas the drug, DOX, was con-
jugated to the SPIO particles via pH-sensitive hydrazone bonds.
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Table 1 | Outline of representative recent examples of polymer-based targeted delivery studies using αvβ3 and/or αvβ5 integrin ligands.
Carrier system Targeting motif Drug Cellular system Results and characteristics (reference)
Cholesterol/DOPE/
DSPC/DSPE-(PEO)4-
cRGDfK/DSPE-
mPEG2000
cRGDfK DOX R40P murine pancreatic
and SN12C renal
carcinoma cells
Fifteen fold increase in drug efficacy relative to animals
treated with free drug (95)
PLG-PEG micelles cRGDfC DOX U87MG human
glioblastoma cells
pH-sensitive drug release, higher cellular uptake, higher
accumulation at tumor sites as monitored by positron
emission tomography (PET) and ex vivo fluorescence
experiments (96)
PLGA-4-arm-PEG
branched NPs
cRGDfC – Pancreatic tumor in mice
and U87MG glioma cells
Efficient uptake by U87MG glioma cells over-expressing
αvβ3. Highest accumulation at tumor site as monitored by
whole body imaging. Low in vivo inherent physiological
toxicity for the NPs (97)
PGA-PTX-E-
[c(RGDfK)]2
conjugate NPs
cRGDfK PTX 4T1 murine breast cancer
tumors
Augmented antitumor activity and reduced systemic toxicity
for PTX, blockade of endothelial cell migration to VEGF and
adhesion to fibrinogen. Lysosomal enzyme assisted release
of PTX is observed (98)
PLGA-PEG NPs GRGDS and RGD
peptidomimetic
PTX and DOX HUVECs and syngenic TLT
cells
High cellular uptake in vitro, improved anticancer efficacy
and higher survival rate of mice (99)
cRGDyK-PEG-
PLA-PTX micelle
cRGDyK PTX Intracranial glioblastoma
model
2.5-Fold increase in antiglioblastoma cell cytotoxicity effect
over non-targeted system, improved drug accumulation,
increase in life time of diseased mice (100)
FOR OTHER STUDIES USING PLGA-PLL NPs PLEASE SEE REF. (101, 102)
HPMA copolymers cRGDfK Geldanamycin PC-3 and DU145 prostate
cancer cell lines
Tumor growth inhibition activity as efficient as free drug,
decrease in IC50 values for targeted conjugates.
Improvements in biodistribution profile, both in vitro and
in vivo antiangiogenic, and antitumor activities for targeted
systems (103–105)
HPMA copolymers cRGDfK Docetaxel PC-3 and DU145 prostate
cancer cell lines
Inhibition of PC3, DU145 cell growth and also of HUVECs
in vitro. In vivo tumor regression is also observed (106)
PCL-PEEP and
Mal-PEG-PCL
micelles
Tf and cRGDfK PTX BMEC and U87MG glioma
cells
Double targeting by Tf and RGD ligand. Uptake of micelles
increased 2.4 times for BMEC compared to micelles lacking
Tf. High drug accumulation in brain upon IV injection (107)
HPAE-co-PLA/DPPE
polymer NPs
Tf and cRGDfK PTX HUVECs and HeLa cells In vitro cytotoxicity for NPs coated with cRGD is increased
10 times in αvβ3-expressing HUVECs while Tf targeting to Tf
receptor over-expressed HeLa cells lead to twofold increase.
pH-sensitive intracellular drug release (108)
PFC
(perfluorocarbon)
NPs
Non-peptidic αvβ3
antagonist
Fumagillin Vx-2 adenocarcinoma
tumor
Diminished development of tumor neovasculature and
reduced tumor growth are observed at much lower drug
concentrations compared to the previous concentration
used in rodent and human clinical trials (109)
P(PEGMEMA) based
micelles
RGD Albendazole OVCAR-3 ovarian cancer
cells
Improved cellular uptake of polymeric micelles and 80% cell
deaths at a micelle concentration of 10µg mL−1 (110)
The cRGD-conjugated SPIO nanocarriers exhibited higher cellular
uptake and cytotoxicity in U87MG cells compared to cRGD-free
systems. Also, in vivo PET imaging of U87MG tumor-bearing
mice revealed increased tumor accumulation of cRGD-SPIO NPs
compared to cRGD-free counterparts. Intracellular specific drug
release by SPIOs was facilitated by pH-selective cleavage of the
SPIO-DOX hydrazone linkage. Such multifunctional systems that
are able to simultaneously target a cell or tissue, deliver a drug, and
provide a diagnosis are known as theranostics, which constitute an
upcoming area of research.
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TARGETED DELIVERY OF GENE THERAPY
Delivery of gene therapy using targeted non-viral vehicles has been
widely studied (20). A directed delivery of DNA or RNA fragments
is required to prevent from using high doses, which otherwise
can lead to off-target gene silencing effects. Using carrier systems
for gene therapy is advantageous as it reduces the problems of
biodegradability, nucleosomal cleavage, and size and charge lim-
ited membrane impermeability associated with the delivery of
nucleic acids. As mentioned earlier, non-viral vectors are also help-
ful to overcome complications and safety issues described for viral
vectors. Here,we briefly tabulate some recent targeted gene therapy
studies (Table 2).
Table 2 | Outline of recent targeted gene delivery studies using αvβ3 and/or αvβ5 integrin ligands.
Carrier system Targeting motif Gene Cellular system Results and Characteristics (reference)
PEG-PLys polyplex
micelle
cRGDfK Luc-pDNA HeLa cells and 293T cells Enhanced transfection efficiency (TE) and perinuclear
accumulation of pDNA within 3 h of incubation (111)
PEG-PLys polyplex
micelle: cross-linked
by thiolation
cRGDfK Luc-pDNA HeLa cells and 293T cells Improvements in TE, selection of endocytotic pathways and
regulation of intracellular trafficking by cRGD. Preferential
caveolae mediated endocytosis is observed. Thiol
cross-linking helped polyplex stabilization and pDNA
protection (112)
PEG-PLys polyplex
micelle: cross-linked
by thiolation
cRGDfK sFlt-1 BxPC-3 pancreatic
adenocarcinoma tumors
Upon IV injection, significant tumor-specific TE and gene
expression is observed which lead to a decrease in tumor
vasculature. Thiol cross-linking has to be optimized to
improve results (113, 114)
PEG-PEI polyplex
micelles
B6 peptide and
RGD bicyclo
peptide
pCMVLuc DU145 and PC3 prostate
cancer cells
Significant improvement in TE via targeting. RGD helped in
initial association of polyplexes to cells whereas the
internalization is observed to be mediated by TfR
endocytosis (115)
PEG-PEI polyplex
micelles
Non-cyclic RGD-
peptidomimetic
MeWo and A549 cells Increased binding, uptake, and luciferase transgene
expression in model cells (116)
PEG-PEI polyplex
micelles
cRGDyK pORF-hTRAIL Intracranial U87
glioblastoma tumor
xenografts
Higher gene transfection and increased therapeutic
efficiency of TRAIL are observed and is reflected in
improved longevities of mice (117)
DNA/PEI-Au-RGD
nanoclusters
Cap-RGD pEGFP-Luc HeLa cells A 5.4- to 35-fold increase in TE corresponding to a low or
high density of αvβ3 on HeLa cells. Observed TEs are far
higher than that for targeted or untargeted commercial
transfection vector – JetPEI. Higher concentration of gold
NPs is found to be toxic (118)
PEG–oligo(ethane
amino) amide
polymers
B6 peptide or
cRGDfK
pEGFP-Luc Mouse N2A
neuroblastoma and DU145
human prostate
adenocarcinoma cells
Selective binding and transfection efficiency are observed
which are mediated by the targeting ligands. The carrier
systems however required use of endosomolytic agents for
release of polyplexes from endosomes (119)
DCP-TEPA
polycation liposomes
cRGDfK siLuc2 B16F10-luc2 murine
melanoma cells
Successful targeting, transfection, and knockdown of luc2
expression in vitro in B16F10-luc2 cells and also in vivo as
monitored by imaging in mice with tumor-bearing lungs, is
observed (120)
PEO-b-PCL micelles RGD4C mdr1 siRNA
and DOX
MDA435/LCC6 cells
resistant to DOX
The system is decorated with cell penetrating peptide (TAT)
as well. Dual functional micelles showed improved cellular
uptake and mdr1 activity leading to lowered P-gp expression
both at the mRNA and protein levels. These effects caused
reversal of MDR for DOX, which increased DOX
accumulation in cytoplasm and nucleus, and enhanced DOX
cytotoxicity (121)
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PHOTOTHERAPY USING TARGETED SYSTEMS
Gormley et al. have tested the use of targeted gold nanorods
(GNRs) for plasmonic photothermal therapy (PPTT) aiming at
reducing the amount of heat required in thermal therapy (51).
To this end, PEGylated GNRs were prepared and functionalized
with cRGDfK via thiol chemistry. Studies on HUVEC and DU145
prostate cancer cells showed effective in vitro selective target-
ing of RGD-GNRs to both these cell types but not in vivo in a
DU145 mice model. The absence of in vivo effects was attrib-
uted to faster clearance of GNRs from physiological system due
to the presence of negative charges in cRGDfK-functionalized
GNRs. On similar lines, for PPTT, Akhavan et al. have pro-
jected reduced single layer graphene oxide nanorods (GONRs)
functionalized by amphiphilic PEG polymers containing RGD-
based peptides (52). RGD-presenting GONRs showed increased
radiation absorption compared to non-functionalized GONRs
and also improved destruction of U87MG human glioblastoma
cells at reduced doses as low as 1µg mL−1. Irradiation for 8 min
with near-infrared radiation at this concentration resulted in
remarkable values of cell destruction (≥97%). On the con-
trary, <11% of cell destruction and 7% of DNA fragmenta-
tion were observed for non-targeted nanorods using the same
concentration.
TARGETING THE α5β1 INTEGRIN
In addition toαvβ3 andαvβ5,an upregulated expression of α5β1 in
tumor vasculature and other cancer cells has also been described
(36, 53–57). α5β1 primarily recognizes fibronectin through the
RGD binding motif. Kim et al. have reported that α5β1 inhibition
induces cell apoptosis in endothelial cells (58) and also showed that
this integrin mediates the migration of endothelial cells. Notewor-
thy, it has been shown that α5 might substitute the activity of αv
during vasculature remodeling (59). For these reasons, targeting
of this integrin has also been approached in cancer therapy.
Kokkoli and co-workers have explored α5β1 integrin for tar-
geting cancer cells by using a fibronectin mimetic α5β1-selective
RGD-containing peptide, named PR_b (60) (Figure 2). This group
produced DPPC-based liposomal NPs covered by PEG and further
decorated with PR_b peptide, and studied their targeting capacity
in a CT26.WT mouse colon carcinoma experimental model. The
quantities of PEG and peptide were fine-tuned in order to optimize
the delivery of the nanovector. By increasing the quantity of conju-
gated peptide, an enhancement in binding of liposomes to cells was
observed, whereas the opposite effect was found when the concen-
tration of PEG was augmented. The cytotoxicity of 5-Fluorouracil
carried by these PR_b targeted liposomes was found to be compa-
rable to that of the free drug and better than that of the particles
containing only the control GRGDSP sequence, confirming the
importance of targeting α5β1 on this cancer model. Similar results
were obtained in studies using HCT116 and RKO human colon
cancer cells (60). This liposomal system has been further investi-
gated for the delivery and cytotoxicity of DOX to MDA-MB 231
breast cancer cells (61). Confocal microscopy experiments showed
that these targeted liposomes were internalized in breast cancer
cells via an endocytic pathway, and transferred within the first
minutes into early endosomes, and after prolonged times into late
endosomes and lysosomes. Particularly at high concentrations, the
therapeutic effect of encapsulated DOX in MDA-MB 231 cells was
comparable to that of the free DOX.
In a recent approach, PR_b targeted polymersomes have also
been explored for siRNA delivery (62). T47D breast cancer cells
were studied to check the expression of Orai3. The downregula-
tion of Orai3 levels results in cell apoptosis. The delivery of Orai3
by PR_b-conjugated polymersomes decreased the viability of can-
cer cells but did not affect non-cancerous MCF10A breast cells.
When compared to a commercial transfection agent (Lipofecta-
mine RNAiMAX), the observed therapeutic effect of the polymer-
some formulation is still moderate. However, this method has not
shown any systemic toxicity unlike other transfection reagents.
TARGETING THE αvβ6 INTEGRIN
The integrin subtype αvβ6 is expressed at low or undetectable
levels in most adult epithelia, but may be upregulated during
inflammation and wound healing (8). αvβ6 preferentially binds
to TGF-β1 latency associated peptide (LAP) (63), but can also rec-
ognize the ECM proteins tenascin and fibronectin (64). In this
regard, αvβ6 is biologically important for the activation of TGF-
β1 and has been shown to control TGF-β activity or signaling
in fibrosis and to play a crucial role in TGF-β-integrin crosstalk
in carcinomas (65). Furthermore, αvβ6 was found to be signifi-
cantly upregulated in tumor tissues (8) and in certain cancer types
including colon (66), ovarian carcinoma (67), and in early stage
of non-small cell lung cancer (NSCLC), which is associated with
poor patient survival (68, 69). Other studies have shown that αvβ6
expression is correlated with the development of metastasis in
gastric cancer and the enhanced survival and invasive potential of
carcinoma cells (70, 71). This pathological relevance has turned
αvβ6 into a promising target for tumor diagnostics and antitumor
therapy.
To date, several linear and cyclic peptides as well as pep-
tidomimetics have been developed to target specifically the αvβ6
integrin subtype (68, 70, 72–74). For instance, the high affinity
αvβ6-specific 20-mer peptide H2009.1 (75) was conjugated as a
tetramer to a poly-glutamic acid polymer carrying DOX, and was
shown to specifically target αvβ6-expressing cells in vitro (76).
In another work, the selectivity of this peptide toward αvβ6 was
exploited to guide fluorescent quantum dots to lung adenocar-
cinoma cell line H2009 in vitro (68). Recently, this peptide has
also been conjugated to a water soluble PTX conjugate resulting
in selective cytotoxicity for the αvβ6-expressing NSCLC cell line
(77). The conjugate was able to reduce the rate of tumor growth
in vivo, however without an increased benefit over the use of free
PTX. Furthermore, the same peptide was used to investigate the
multimeric effect on functionalized liposomes (78). In this study,
liposomes displaying tetramers of the H2009.1 peptide demon-
strated higher drug delivery and toxicity toward αvβ6-expressing
cells than liposomes displaying single copies of H2009.1, even if
the total number of peptides bound to each liposome was identi-
cal. In another approach, H2009.1 was used to functionalize the
surface of multifunctional micelles encapsulated with SPIO and
DOX for MRI and drug-delivery applications, respectively (79).
The functionalized micelles significantly increased cell targeting
and uptake in αvβ6-expressing H2009 cells, as verified by MRI
and confocal imaging.
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A20FMDV2 (80, 81) is another αvβ6-selecitve 20-mer pep-
tide (Figure 2) that can be used for targeted therapies. As an
example, this peptide was radiolabeled on solid phase using 4-
[18F]fluorobenzoic acid and the conjugate was selectively uptaken
by αvβ6-positive tumors but not by αvβ6-negative tumors, as
monitored in mice by PET (70). In a similar approach,A20FMDV2
was conjugated to 5-[18F]fluoro-1-pentyne via an azide-based 1,3-
dipolar cycloaddition (click chemistry). However, no difference
in tumor targeting in vivo was observed for such strategy com-
pared to the previous labeling method (82). 18F-labeled derivatives
of the same peptide were described to improve tumor uptake
capacity in BxPC-3 (pancreatic cancer) xenograft-bearing mice
over [18F]-FDG (83). Recently, A20FMDV2 was conjugated to
an 18F-based tracer by copper-free, strain promoted click chem-
istry. However, the resulting derivative did not show a remarkable
in vivo tumor uptake by mouse with mouse model DX3puroβ6-
tumor (84). Furthermore, A20FMDV2 was conjugated to DTPA
and labeled with 111In for SPECT imaging. In this study, the
conjugate showed specific localization in αvβ6-tissues, and dis-
played increased uptake in an αvβ6-positive tumor and in a mouse
xenograft model bearing breast tumors that express αvβ6 endoge-
nously (85). Additionally, A20FMDV2 was incorporated into a
recombinant adenovirus type 5 (Ad5) leading to increased cyto-
toxicity on a panel of αvβ6-positive human carcinoma cell lines
in vitro and enhancement in tumor uptake and improved tumor
transduction in an αvβ6-positive xenograft model in vivo over the
Ad5 wild type (86).
In another approach pursued by the Gambhir research group,
cystine knot peptides showing high affinity for αvβ6 but none
for the related subtypes αvβ3, αvβ5, and α5β1 were developed
and conjugated to 64Cu-DOTA for PET-based tumor imaging
(87). Injection of these conjugates into mice bearing either αvβ6-
positive BxPC-3 xenografts or αvβ6-negative tumors, and mon-
itoring by PET imaging, showed αvβ6-selective targeting for the
tumors expressing αvβ6. In a recent study (88), two cystine knot
peptides were labeled with 18F-fluorobenzoate and their capac-
ity to be uptaken by tumor cells assessed in vivo. PET imaging
revealed for both peptides specific targeting of αvβ6-positive
BxPC-3 xenografted tumors over αvβ6-negative HEK 293 tumors.
These results illustrate the potential of the described strategies
to be clinically used in PET imaging of αvβ6-over-expressing
tumors.
CONCLUDING REMARKS
A wide variety of carrier systems have been described to achieve
tumor-specific therapeutic effects via integrin targeting. The prin-
cipal success of this strategy is evidenced by two main obser-
vations – the dosage of drug has been usually reduced and an
enhanced (and often selective) activity against tumors is achieved.
The data obtained from independent studies using different car-
rier systems are promising and there is therefore hope to bring the
targeted delivery methods into practice. However, a number of
aspects related to the use of these drug-delivery systems in cancer
therapy should be carefully considered.
In the first place, comparative studies between distinct carrier
systems are missing. Such studies could provide useful insights
on their relative advantages and disadvantages, and help in their
further development and optimization. Detailed studies con-
cerning the systemic toxicity and long-term side effects of the
drug-delivery vectors in physiological systems are also essen-
tial. Another important aspect to optimize the concentration of
drugs in cancer therapy would be to evaluate the efficiency of
drug uptake with regard to the overall administered dose, but
most studies have only rated the efficiency of the targeted sys-
tems in comparison to untargeted systems, without mentioning
about the concentrations of the drug used. The investigation of
the metabolic stability of these systems in gut and liver as well
as their bioavailability profile would also be crucial to improve
the efficacy of the therapy. Further optimization of such drug
formulations could be directed toward new routes of admin-
istration, including, though certainly difficult, orally available
conjugates.
It should be mentioned that most studies in this field rank the
antitumor potency of the targeted systems based on the reduc-
tion in tumor volume and size, parameters that will however
not entirely assure the success of the therapy. More satisfactory
would be to carry out longer experiments to ensure the com-
plete removal of tumors and arrest of resurrections. In this regard,
recent findings have suggested that antiangiogenic therapeutics
that aim at treating cancer primarily through reduction and con-
trol of tumor growth, may, in some cases, indirectly promote
cancer invasiveness and metastasis (89, 90). This ultimately alarms
development of targeted therapies which can inhibit multiple cel-
lular functions and affecting not only cell survival in situ but
also mechanisms involved in the promotion and progression of
metastasis. Further investigations on this matter should include
the study of targeted therapy on early stage and late stage tumors,
and the effect (if any) of these strategies in the development of
drug resistance mechanisms by some tumors. Additionally, treat-
ment of cancer often necessitates a combination therapy (com-
bination of different therapeutics or therapies). In this respect,
it is demanding to study the usage of targeted approaches for
delivering multiple drugs or therapies either by a single carrier
system or multiple carrier systems. These studies are further pend-
ing in literature. Most of the studies on targeted gene delivery
have used luciferase model system. Though it is a good analo-
gous system for understanding gene delivery, proper experimental
gene therapy studies aimed to treat cancers are to be extensively
studied.
The choice of an optimal integrin ligand is another aspect
of paramount importance in the design of integrin-based tar-
geted therapies in cancer. This will depend on the differential
pattern of integrin expression in cancer cell types and the bio-
logical activity and selectivity profiles of the targeting ligands.
Many applications have used linear or cyclic RGD peptides to
deliver drugs or nucleotides to tumors. Most of these peptides
are active for αvβ3; however, it is often ignored that these lig-
ands may target other integrin subtypes as well. This might not
be relevant as long as simplified cellular or experimental animal
models are investigated. However, it may raise safety concerns
if clinical applications in humans are to be envisaged. E.g., the
habitually used peptide – c(RGDfX), developed in our group long
ago (25, 30), has about 1 nM affinity for αvβ3 and is certainly
selective against αIIbβ3 (low affinity for the platelet receptor).
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Nonetheless, the compound also has affinity in the low nanomo-
lar range for αvβ5 (7.6 nM) and α5β1 (15 nM) (73). Thus, the
use of c(RGDfX) might not always provide enough selectivity to
distinguish between distinct cell types. In this regard, our group
has recently developed (91, 92) and functionalized (93, 94) pep-
tidomimetics which can clearly discriminate between αvβ3 and
α5β1. Application of such single integrin subtype selective ligands
will enable a selective and controlled delivery of drugs to tumors,
taking advantage of the distinct patterns of integrin expression
found for each cancer type.
It is on the basis of these considerations that targeted therapy
with integrin ligands be translated into clinical studies, and be
demonstrated whether such strategy will result in a clear benefit
for cancer patients.
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